palmitoylethanolamide.com.au
HomeResearchD'Ascanio 2021

Randomized clinical trial "olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin": preliminary results

D'Ascanio L, Vitelli F, Cingolani C, Maranzano M, Brenner MJ, Di Stadio A. Eur Rev Med Pharmacol Sci. 2021;25(11):4156-4162.

Randomised controlled trialHumansWith luteolin

This study tested palmitoylethanolamide together with luteolin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design
Randomised controlled trial
Subjects
12 outpatients with smell loss persisting at least 90 days after a negative COVID-19 test: 7 supplement plus olfactory rehabilitation, 5 olfactory rehabilitation alone
Dose used in the study
Daily oral PEA plus luteolin supplement with weekly olfactory rehabilitation, versus twice-daily olfactory rehabilitation alone
Duration
30 days
What was measured
Sniffin' Sticks threshold, discrimination and identification at baseline and day 30

What the authors reported

The supplement group improved more on the Sniffin' Sticks score than controls (p = 0.01). Longer time since infection was associated with lower scores. No association with gender.

Limits of this study

Pilot with 12 patients. No placebo and no blinding described in the abstract. The rehabilitation schedule differed between arms (weekly versus twice daily), so the comparison is not of the supplement alone. 30 days only. Same research group as the later, larger trials. Dose not stated in the abstract.

Source

PubMed 34156697 · doi:10.26355/eurrev_202106_26059

Entry checked against the abstract, supplied by Devlin. Dose and blinding were not in the abstract on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.